title: [Epidermal growth factor receptor (EGFR): therapeutic target in the treatment of lung adenocarcinoma].
abstract: Revolution in biotechnology made possible to identify those gene errors, which via their encoded proteins (mostly kinase enzymes) are key players in tumor development, growth and progression, and could be considered as molecular targets in tumor diagnosis and therapy. Activity of EGFR (epidermal growth factor receptor), an outstanding representative of the regulatory cell surface receptors, can be inhibited by drugs proved for clinical use. In the past year many groups observed that those lung adenocarcinoma cells, which contain activating mutation in the tyrosine kinase domain of EGFR show remarkable sensitivity to anti-EGFR compounds. The basis of the effective therapy is the identification of the mutations. The clinical advantage of EGFR is an example from the coming age of tumor chemotherapy, when the presence of molecular targets will guide the therapeutic choice.
authors.affiliation: Semmelweis Egyetem, Altalános Orvostudományi Kar, I. Patológiai es Kísérleti Rákkutató Intézet.
authors.forename: Richárd
authors.initials: R
authors.lastname: Schwab
authors.forename: István
authors.initials: I
authors.lastname: Peták
authors.forename: Ferenc
authors.initials: F
authors.lastname: Pintér
authors.forename: Edit
authors.initials: E
authors.lastname: Szabó
authors.forename: Melinda
authors.initials: M
authors.lastname: Kánya
authors.forename: Anna
authors.initials: A
authors.lastname: Tamási
authors.forename: Edit
authors.initials: E
authors.lastname: Várkondi
authors.forename: Andrea
authors.initials: A
authors.lastname: Almási
authors.forename: Orsolya
authors.initials: O
authors.lastname: Szokolóczi
authors.forename: Judit
authors.initials: J
authors.lastname: Pápay
authors.forename: Judit
authors.initials: J
authors.lastname: Moldvay
authors.forename: György
authors.initials: G
authors.lastname: Kéri
authors.forename: László
authors.initials: L
authors.lastname: Kopper
mesh_terms: D000230:Adenocarcinoma / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000378:metabolism; D066246:ErbB Receptors / Q000187:drug effects* / Q000378:metabolism; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism; D009154:Mutation; D011505:Protein-Tyrosine Kinases / Q000235:genetics
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D066246:ErbB Receptors; D011505:Protein-Tyrosine Kinases